

Contents

| | |
|---------------------------------|-------|
| List of Abbreviations | XXVII |
|---------------------------------|-------|

Screening and Toxicity of Anti-Inflammatory Drugs

CHAPTER 19

Screening and Assessment of the Potency of Anti-Inflammatory Drugs in vitro. R. J. GRYGLEWSKI. With 3 Figures

| | |
|---|----|
| A. Introduction | 3 |
| B. Interaction With Non-Enzymic Proteins | 3 |
| I. Binding to Plasma Proteins | 3 |
| 1. Displacement Reactions | 4 |
| 2. Disulphide Interchange Reactions | 4 |
| 3. Protection Against Protein Denaturation | 4 |
| 4. Fibrinolytic Activity | 5 |
| II. Interaction With Biological Membranes | 5 |
| 1. Effects on Erythrocyte Membrane | 5 |
| 2. Effects on Lysosomal Membrane | 6 |
| 3. Cytotoxic Properties | 7 |
| 4. Effects on Leucocyte Migration | 8 |
| C. Interaction With Enzymic Proteins | 8 |
| I. General Considerations | 8 |
| II. Interaction With Enzymes Involved in Carbohydrate, Protein, and Nucleic Acid Metabolism | 9 |
| 1. Carbohydrate, Protein, and Amino Acid Metabolism | 9 |
| 2. Nucleic Acid and Nucleotide Metabolism | 9 |
| III. Inhibition of Prostaglandin Synthetase | 10 |
| 1. Prostaglandin Synthetase System | 10 |
| 2. Assay of Prostaglandin Synthetase Activity | 11 |
| 3. Prostaglandin Synthetase Inhibitors | 15 |
| 4. Inhibition of Platelet Aggregation | 21 |
| 5. Effects on Smooth Muscle | 25 |
| D. Conclusions | 26 |
| References | 27 |

CHAPTER 20

Inhibition of Erythema and Local Hyperthermia. K. F. SWINGLE, R. J. TRANCIK, and D. C. KVAM. With 4 Figures

| | |
|---|----|
| A. Introduction | 44 |
| B. Ultraviolet (UV) Light and the Erythematous Response | 45 |
| C. Instrumentation | 47 |
| I. Light Sources for Induction of Erythema | 47 |
| II. Measurement of Erythema and Local Hyperthermia | 47 |
| 1. Erythema | 47 |
| 2. Skin Temperature | 47 |
| D. Procedures | 50 |
| I. Erythema | 50 |
| 1. UV-Induced | 50 |
| 2. Thurfyl Nicotinate-Induced | 54 |
| 3. Miscellaneous Procedures for Producing Erythema | 54 |
| II. Local Hyperthermia | 55 |
| 1. Local Hyperthermia in Paws of Rats Injected With Irritants | 56 |
| 2. Local Hyperthermia in UV-Irradiated Skin | 57 |
| E. Inhibition of Erythema and Local Hyperthermia | 58 |
| I. UV-Induced Erythema | 58 |
| 1. Systemic Administration of Drugs | 58 |
| 2. Topically or Intradermally | 62 |
| II. Tetrahydrofurfuryl Nicotinate (THFN) Erythema | 63 |
| III. Other Erythemas | 63 |
| IV. Local Hyperthermia | 63 |
| F. Conclusion | 69 |
| References | 70 |

CHAPTER 21

Oedema and Increased Vascular Permeability. C. G. VAN ARMAN

| | |
|---|----|
| A. General Principles of Assays | 75 |
| I. Statistical Considerations in Assay Work | 79 |
| 1. Relationship of Dose to Effect | 79 |
| 2. Definition of ED ₅₀ | 79 |
| 3. Confidence Limits | 79 |
| 4. Coefficient of Variation | 80 |
| 5. The <i>g</i> Value | 80 |
| 6. The Lambda Value, λ | 80 |
| 7. Errors of Types I and II | 80 |

| | |
|---|----|
| B. Methods for Producing and Measuring Oedema and Increased Vascular Permeability | 81 |
| I. Oedemas of the Rat's Paw | 81 |
| 1. Measurement | 81 |
| 2. Agents Causing Paw Oedema; Characteristics of Oedemas Caused by Several Agents | 82 |
| II. Increased Vascular Permeability | 86 |
| III. Oedema in the Pleural Space | 86 |
| C. Conclusion | 87 |
| References | 88 |

CHAPTER 22

Short-Term Drug Control of Crystal-Induced Inflammation. D. J. McCARTY.
With 4 Figures

| | |
|--|-----|
| A. Historical Aspects | 92 |
| B. Mechanism of Crystal-Induced Inflammation | 93 |
| I. Phagocytosis | 93 |
| II. Membranolysis | 93 |
| III. Inflammatory Mediators | 96 |
| IV. Chemotactic Factors | 97 |
| C. Experimental Models | 98 |
| I. Animal | 98 |
| II. Man | 102 |
| D. Therapy of Acute Attacks of Gout and Pseudogout | 102 |
| I. Gout | 102 |
| II. Pseudogout | 102 |
| E. Summary | 104 |
| References | 104 |

CHAPTER 23

Experimental Models of Arthritis in Animals as Screening Tests for Drugs to Treat Arthritis in Man. M. E. J. BILLINGHAM and G. E. DAVIES. With 2 Figures

| | |
|---|-----|
| A. Introduction | 108 |
| B. Advantages and Disadvantages of Models of Arthritis—Comparison With Acute Models | 108 |
| C. Adjuvant-Induced Arthritis | 109 |
| I. First Observation. First Use as a Screen for Anti-Inflammatory/Antirheumatic Drugs | 110 |
| II. Production | 112 |
| 1. Adjuvant | 112 |
| 2. Route of Injection | 114 |

| | |
|---|-----|
| 3. Species Variation and Strain Variation | 114 |
| 4. Time Course of the Disease | 115 |
| III. Aetiology | 116 |
| 1. Role of Lymphatic System | 116 |
| 2. Immunological Mechanisms | 116 |
| 3. Histology | 117 |
| 4. Lysosomal Enzymes | 118 |
| IV. Assessment | 118 |
| 1. Physical Assessment—Gross Measurements | 119 |
| 2. Physiological/Functional Parameters | 120 |
| 3. Biochemical Parameters | 120 |
| 4. Period of Dosing of Compounds | 123 |
| V. Effect of Drugs | 124 |
| 1. Non-Steroid Anti-Inflammatory Drugs | 124 |
| 2. Steroid Anti-Inflammatory Drugs | 125 |
| 3. Gold, Chloroquine, and Penicillamine | 125 |
| 4. Immunosuppressant Drugs | 127 |
| 5. Antilymphocytic Serum, Antigens | 127 |
| 6. Non-Specific Inhibition | 129 |
| 7. The Effect of Adjuvant Arthritis on Drugs | 130 |
| D. Arthritis Produced by Intra-Articular Injection of Antigens and Antibodies | 131 |
| E. Arthritis Produced by Intra-Articular Injection of Lysosome Labilisers | 133 |
| F. Arthritis Induced by Infectious Agents | 134 |
| E. Conclusions | 134 |
| References | 135 |

CHAPTER 24

Antagonism of Bradykinin Bronchoconstriction by Anti-Inflammatory Drugs.

P. J. PIPER and J. R. VANE

| | |
|---|-----|
| A. Introduction | 145 |
| B. Production of Kinins and Other Mediators of Anaphylaxis in the Lungs | 146 |
| I. In vitro | 146 |
| II. In vivo | 146 |
| III. Release of Catecholamines in vivo | 146 |
| C. Action of Bradykinin on Lung Function | 147 |
| I. Bronchial Smooth Muscle in vitro and in vivo | 147 |
| II. Pulmonary Circulation | 148 |
| D. Release of Prostaglandins and Precursors From Lungs by Bradykinin | 148 |
| E. Actions of Prostaglandins in the Lungs | 150 |
| I. Bronchial Smooth Muscle | 150 |
| F. Interaction of Bradykinin With Prostaglandins in the Lungs | 153 |
| I. As a Mediator | 153 |
| II. As a Potentiator | 153 |
| III. As a Mediator of Vascular Leakage | 154 |

| | |
|---|-----|
| G. Metabolism of Kinins in the Pulmonary Circulation | 154 |
| H. Inhibition of Bronchoconstriction by Anti-Inflammatory Acids | 155 |
| I. In vivo and in vitro Studies | 155 |
| II. Comparison With Other Bronchoconstrictor Agents | 156 |
| I. Possible Actions and Interactions of Kinins and Prostaglandins in Asthma | 157 |
| J. Summary and Conclusions | 158 |
| References | 158 |

CHAPTER 25

Interference of Anti-Inflammatory Drugs With Hypotension. B. B. VARGAFTIG.
With 11 Figures

| | |
|---|-----|
| Introduction | 164 |
| A. Interference of Non-Steroidal Anti-Inflammatory Drugs With Hypotensive Effects of Potential Inflammatory Mediators | 164 |
| I. Kinin Peptides | 164 |
| II. Prostaglandins | 165 |
| B. Interference by Non-Steroidal Anti-Inflammatory Drugs With the Hypotensive Effects of Agents That Release Potential Inflammatory Mediators | 166 |
| I. Proteolytic Enzymes | 166 |
| 1. Kininogenases | 167 |
| 2. Thrombin | 168 |
| 3. Other Proteolytic Enzymes | 169 |
| II. Inhibition of Hypotension Due to Substances That Activate Plasma Kininogenase | 169 |
| 1. Carrageenin | 169 |
| 2. Other Activators of Plasma Kininogenase | 171 |
| III. Phospholipase A ₂ | 171 |
| C. Interference of Anti-Inflammatory Drugs With Hypotensive Responses to Lipid Derivatives | 173 |
| I. Effects of Arachidonic Acid on Arterial Blood Pressure | 174 |
| 1. Mechanism of Action of Arachidonic Acid on Blood Pressure | 174 |
| II. Effects of Fatty Acids Other Than Prostaglandin Precursors | 180 |
| III. Slow Reacting Substance C | 181 |
| 1. Mechanism of Action of Slow Reacting Substance C | 184 |
| D. Interference of Non-Steroidal Anti-Inflammatory Agents With Effects of Miscellaneous Agents | 185 |
| I. Adenosine Nucleotides | 185 |
| II. Collagen | 186 |
| III. Anaphylatoxin | 187 |
| IV. Depressor Active Substance (DAS) | 187 |
| V. Platelet Clumping Substance | 187 |
| VI. Barium Sulphate and Other Particulate Materials | 187 |

| | |
|---|-----|
| E. Interference of Non-Steroidal Anti-Inflammatory Agents With Hypotension in Endotoxin Shock | 188 |
| I. Dogs | 188 |
| II. Cats | 188 |
| III. Other Animal Species | 190 |
| F. Mechanism of Action of Hypotensive Agents Liable to Inhibition by Non-Steroid Anti-Inflammatory Drugs | 190 |
| I. Structure-Activity Correlations | 190 |
| 1. Thiol and Anti-Oxidant Compounds | 191 |
| II. Stereospecificity | 192 |
| III. Mechanism of Action of Hypotensive Agents Subject to Inhibition by Non-Steroidal Anti-Inflammatory Drugs | 194 |
| 1. Bradykinin | 194 |
| 2. Collagen | 194 |
| 3. Carrageenin | 195 |
| 4. Adenosine Nucleotides | 195 |
| IV. Conclusions | 196 |
| 1. Relevance of Hypotensive Responses to Inflammation and to Study of Inflammatory Events | 196 |
| 2. Multisequential Activation and Acute Hypotensive Responses: Prospects of Research | 197 |
| References | 198 |

CHAPTER 26

Antagonism of Pain and Hyperalgesia. R. VINEGAR, J. F. TRUAX, J. L. SELPH, and P. R. JOHNSTON. With 3 Figures

| | |
|--|-----|
| A. Introduction | 209 |
| I. Terminology | 209 |
| II. Historical Introduction to Analgesic Testing in Hyperalgesic Animals | 210 |
| B. Non-Hyperalgesic Mild Analgesic Assays | 218 |
| I. Stretching Tests | 218 |
| C. Assessment of Mild Analgesia in Humans | 219 |
| I. Clinical Evaluation of Mild Analgesic Agents | 219 |
| D. Conclusion | 220 |
| References | 221 |

CHAPTER 27

Inhibition of Cell Migration in vivo and Granuloma Formation. M. DI ROSA

| | |
|--|-----|
| A. General Introduction | 223 |
| I. Mechanisms of Cell Migration | 223 |
| II. The Sequence of Cell Migration | 225 |

| | |
|--|-----|
| III. Fate of Emigrated Cells | 225 |
| 1. Polymorphs | 225 |
| 2. Mononuclear Cells | 226 |
| IV. Granuloma Formation and Evolution | 227 |
| B. Models for Leucocyte Emigration in vivo | 228 |
| I. Generalities | 228 |
| II. Histological Method | 229 |
| III. Cell Collection From Cavities | 229 |
| 1. Natural Cavities | 229 |
| 2. Artificial Cavities | 231 |
| IV. Cell Collection From Early Granulomata | 232 |
| V. Cell Labelling | 232 |
| C. Models for Granuloma Formation in vivo | 233 |
| I. Cotton-Pellet Granuloma | 233 |
| II. Granuloma Pouch | 234 |
| III. Carrageenin Granuloma | 235 |
| IV. Plastic Ring Granuloma | 235 |
| V. Filter Paper Granuloma | 235 |
| D. Inhibition of Cell Migration in vivo | 236 |
| I. Steroids | 236 |
| 1. Neutrophils | 236 |
| 2. Mononuclear Cells | 237 |
| II. Non-Steroid Anti-Inflammatory Drugs | 238 |
| III. Immunosuppressive Agents | 240 |
| IV. Endogenous Substances | 241 |
| E. Inhibition of Granuloma Formation | 242 |
| I. Steroid Anti-Inflammatory Drugs | 242 |
| II. Non-Steroid Anti-Inflammatory Drugs | 243 |
| III. Immunosuppressive Agents | 243 |
| IV. Endogenous Substances | 244 |
| F. Conclusions | 244 |
| References | 245 |

CHAPTER 28

Inhibition of Fever. C. ROSENDORFF and C. J. WOOLF. With 3 Figures

| | |
|--|-----|
| A. Introduction | 255 |
| B. Pathogenesis of Fever | 255 |
| I. Exogenous and Endogenous Pyrogen | 255 |
| II. Site of Action of Pyrogens | 256 |
| III. Mechanism of Action of Pyrogens | 257 |
| 1. Change in Set-Point or Gain? | 257 |
| 2. Role of Prostaglandins | 257 |
| 3. Role of Monoamines and Cyclic-AMP | 258 |
| 4. Ionic Mechanisms in Fever | 259 |

| | |
|---|-----|
| C. Antipyretics | 259 |
| I. Possible Sites of Action of Antipyretics | 260 |
| 1. Inactivation of Bacterial Pyrogen (Site I) | 261 |
| 2. Inhibition of Endogenous Pyrogen Production or Release (Site II) | 261 |
| 3. Inhibition of Endogenous Pyrogen Activity (Site III) | 262 |
| 4. Access of Endogenous Pyrogen to the Central Nervous System (Site IV) | 262 |
| 5. Hypothalamic Thermoregulatory Centres (Site V) | 262 |
| 6. Suppression of Heat Production (Site VI) | 262 |
| II. Possible Mechanisms of Antipyretic Action | 264 |
| 1. Inhibition of Prostaglandin Synthesis/Release | 264 |
| 2. Competitive Antagonism Between Pyrogens and Antipyretics for a Receptor Site | 265 |
| 3. Alteration in the Activity of Neurones in the Hypothalamus | 266 |
| III. Antipyresis | 271 |
| D. Inhibition of Fever by Other Means | 271 |
| I. Increased Heat Loss | 271 |
| II. Monoamine Blockade and Depletion | 272 |
| III. Cholinergic Blockade | 272 |
| E. Conclusion | 272 |
| References | 274 |

CHAPTER 29

Evaluation of the Toxicity of Anti-Inflammatory Drugs. P. W. DODGE, D. BRODIE, and B. D. MITCHELL

| | |
|---|-----|
| A. Introduction | 280 |
| I. Historical Overview | 280 |
| B. Evaluation of Toxicity in Man | 281 |
| I. Gastrointestinal Tract | 282 |
| II. Central Nervous System | 283 |
| III. Dermatological Disorders | 283 |
| IV. Haematopoietic System | 283 |
| V. Ocular Disturbances | 284 |
| VI. Renal Side Effects | 284 |
| VII. Miscellaneous Side Effects | 284 |
| C. Methods Used to Evaluate Toxicity in Animals | 284 |
| I. Gastrointestinal | 285 |
| II. Kidney | 286 |
| III. Haematopoietic System | 287 |
| IV. Liver | 287 |
| V. Skin | 288 |
| VI. Eye | 289 |
| VII. Central Nervous System | 289 |

| | |
|--|-----|
| D. Correlation of Experimental Models With Clinical Toxicity | 289 |
| I. Non-Steroid Anti-Inflammatory Drugs | 289 |
| 1. Salicylates | 289 |
| 2. Indomethacin | 292 |
| 3. Phenylbutazone | 293 |
| 4. Arylalkanoic Acids | 293 |
| 5. Gold | 294 |
| II. Steroids | 294 |
| E. Summary | 295 |
| References | 296 |

Pharmacology of the Anti-Inflammatory Agents

CHAPTER 30

Prostaglandin Synthetase Inhibitors I. T. Y. SHEN. With 1 Figure

| | |
|---|-----|
| A. Introduction | 305 |
| B. Inhibition of Synthetase by Substrate Analogues and Fatty Acid Derivatives | 308 |
| I. Unsaturated Fatty Acids | 308 |
| II. Bicyclic Analogues | 310 |
| C. Regulation of Enzymic Factors: Co-Factors, Stimulation, and Catabolism | 310 |
| I. Regulation of Biosynthesis | 310 |
| II. Catabolic Enzymes | 313 |
| D. Inhibition by Non-Steroid Anti-Inflammatory Agents | 313 |
| I. An Overview of Structure-Activity Relationship | 313 |
| 1. Correlation of PG Synthetase Inhibition With Anti-Inflammatory Action | 313 |
| 2. General Structure-Activity Relationship | 315 |
| II. Salicylates | 316 |
| III. Indomethacin, Sulindac, and Congeners | 317 |
| IV. Substituted Aryl Aliphatic Acids | 321 |
| V. Fenamates | 323 |
| VI. Other Acidic Anti-Inflammatory Agents | 325 |
| VII. Non-Acidic Anti-Inflammatory Agents | 327 |
| E. Effects of Corticosteroids | 329 |
| F. Inhibition and Stimulation by Other Pharmacological Agents | 329 |
| I. Anti-Arthritic and Related Compounds | 329 |
| II. Psychotropic Drugs | 331 |
| III. Sulphydryl Reagents and Derivatives | 332 |
| IV. Hormones and Mediators | 333 |
| V. Inactive Pharmacological Agents | 334 |
| G. The Search for New Inhibitors | 335 |
| I. Current Research Trend | 335 |
| II. Biochemical and Physiological Specificity | 336 |
| III. Pharmacodynamic and Metabolic Control | 337 |

| | |
|--|-----|
| IV. Multiple-Action Inhibitors | 338 |
| V. Synthetic and Physicochemical Approaches | 339 |
| H. Pharmacokinetics of Prostaglandin Synthetase Inhibitors | 340 |
| I. Conclusion | 341 |
| References | 342 |

CHAPTER 31

Mode of Action of Anti-Inflammatory Agents Which are Prostaglandin Synthetase Inhibitors. S. H. FERREIRA and J. R. VANE. With 2 Figures

| | |
|--|-----|
| A. Mediators and Inflammatory Responses | 348 |
| B. Mechanism of Anti-Inflammatory Action | 351 |
| I. Action on Step 1: Diminution of the Capability of Tissue Cells to Respond to Inflammatory Mediators | 352 |
| 1. Increased Dilatation and Vascular Permeability | 353 |
| 2. Pain and Hyperalgesia | 354 |
| 3. Increased Fibroblast Proliferation and Secretion | 354 |
| II. Action on Step 2: Pharmacological Receptor Antagonism | 355 |
| III. Action on Step 3: Inhibition of Extracellular Enzymic Activities Which Generate Inflammatory Mediators or Cause Injury to Cell Membranes and/or Tissue Components | 356 |
| IV. Action on Step 4: Inhibition of the Release of Intracellular Lytic Enzymes or Mediator-Genases or Stored Receptor-Mediators | 358 |
| V. Action on Step 5: Inhibition of the Synthesis of Inflammatory Mediators | 360 |
| 1. Prostaglandin Synthesis and Release | 361 |
| 2. Prostaglandins and Inflammatory Signs and Symptoms | 363 |
| 3. Correlation Between <i>in vitro</i> Inhibition of Prostaglandin Synthesis and Anti-Inflammatory Activity | 368 |
| 4. Inhibition of Prostaglandin Synthesis <i>in vivo</i> and Inflammatory Signs and Symptoms | 370 |
| VI. Action on Step 6: Inhibition of Cell Migration | 374 |
| VII. Action on Step 7: Inhibition of the Generation of the Effective Inflammatory Trauma | 375 |
| C. Side-Effects of Anti-Inflammatory Drugs Which are Prostaglandin Synthetase Inhibitors | 376 |
| D. Theories and Theories | 379 |
| References | 383 |

CHAPTER 32

Penicillamine and Drugs With a Specific Action in Rheumatoid Arthritis. E. C. HUSKISSON. With 8 Figures

| | |
|--|-----|
| A. Classification of Antirheumatic Drugs | 399 |
| B. Penicillamine | 400 |
| I. Actions in Man | 400 |
| II. Possible Mode of Action and Effects in Animal Models | 404 |

| | |
|--|-----|
| C. Gold Salts | 405 |
| D. Chloroquine and Other Antimalarials | 406 |
| E. Levamisole | 407 |
| F. Other Imidazole Derivatives | 409 |
| G. Immunosuppressives | 410 |
| H. Alclofenac | 410 |
| I. Steroids | 411 |
| J. Summary | 411 |
| References | 412 |

CHAPTER 33

Antagonists of Histamine, 5-Hydroxytryptamine and SRS—A. A. F. GREEN, L. G. GARLAND, and H. F. HODSON. With 11 Figures

| | |
|---|-----|
| A. Classification of Antihistamines | 415 |
| B. Histamine H ₁ Antagonists: Structure-Activity Relationships | 415 |
| C. Histamine H ₁ Antagonists: Inhibition of Responses to Histamine Involved in Inflammatory and Anaphylactic Reactions | 419 |
| I. Guinea Pig | 421 |
| II. Rat | 421 |
| III. Rabbit | 422 |
| IV. Mouse | 422 |
| V. Man | 422 |
| D. Histamine H ₂ Antagonists: Chemical Considerations | 423 |
| E. Inhibition of Cardiovascular Responses to Histamine by H ₁ and H ₂ Antagonists | 424 |
| F. Chemical and Pharmacological Classes of 5-Hydroxytryptamine Antagonists | 426 |
| I. Chemical Classes | 426 |
| II. "M" and "D" Receptors | 426 |
| III. "Musculotropic" and "Neurotropic" Receptors | 427 |
| G. Antagonists of 5-Hydroxytryptamine: Inhibition of Responses to 5-HT Involved in Inflammatory and Anaphylactic Reactions | 429 |
| I. Guinea Pig | 429 |
| II. Rat | 429 |
| III. Rabbit | 432 |
| IV. Mouse | 432 |
| V. Man | 432 |
| H. Effects of Antagonists of Histamine (H ₁ Receptors) and 5-HT in Various Types of Inflammation | 432 |
| I. Guinea Pig | 434 |
| 1. Thermal and Ultraviolet Injury | 434 |
| 2. Local Anaphylaxis | 436 |
| 3. Systemic Anaphylaxis | 437 |
| 4. Compound 48/80 and Polymyxin B | 439 |
| 5. Bradykinin | 439 |

| | |
|--|-----|
| II. Rat | 439 |
| 1. Thermal and Ultraviolet Injury | 439 |
| 2. Local Anaphylaxis | 441 |
| 3. Systemic Anaphylaxis | 443 |
| 4. Compound 48/80, Polymyxin, Dextran, and Egg White | 444 |
| 5. Turpentine Pleurisy | 445 |
| 6. Carrageenin Oedema | 446 |
| 7. Croton Oil | 447 |
| 8. Bradykinin | 447 |
| III. Rabbit | 447 |
| 1. Thermal Injury | 447 |
| 2. Anaphylactic Reactions | 447 |
| 3. Inflammation Associated With Bacterial Infections | 448 |
| IV. Mouse | 448 |
| 1. General Anaphylaxis | 448 |
| 2. Cutaneous Anaphylaxis | 449 |
| 3. Other Local Inflammatory Reactions | 450 |
| 4. Systemic Reactions Involving Inflammation | 450 |
| V. Man | 451 |
| 1. Burns | 451 |
| 2. Compound 48/80 and Polymyxin | 451 |
| 3. Hypersensitivity States | 451 |
| 4. Rheumatoid Arthritis and 5-HT Antagonists | 451 |
| VI. Bovine Anaphylaxis | 452 |
| I. Antagonists of SRS-A | 452 |
| I. Non-Steroid Anti-Inflammatory Drugs | 453 |
| II. Polyphloretin Phosphate (PPP) | 454 |
| III. FPL 55712 | 454 |
| IV. Hydratropic Acids | 455 |
| J. Prospects for New Drugs | 456 |
| References | 457 |

CHAPTER 34

Inhibitors of the Release of Anaphylactic Mediators. L. G. GARLAND, A. F. GREEN, and H. F. HODSON. With 26 Figures

| | |
|---|-----|
| A. Characteristics of Anti-Allergic Agents Discussed | 467 |
| B. Cromoglycate and Similar Compounds | 467 |
| I. Identification and Screening | 467 |
| 1. The Passive Cutaneous Anaphylaxis Reaction (PCA) in Rats | 468 |
| 2. Lung Anaphylaxis <i>in vivo</i> | 471 |
| 3. Passive Peritoneal Anaphylaxis | 472 |
| 4. Human Tissues <i>in vitro</i> | 474 |
| 5. Rat Tissues <i>in vitro</i> | 477 |

| | |
|--|-----|
| II. Structure-Activity Relationships | 478 |
| III. Anti-Allergic Properties | 488 |
| 1. Tissue and Species Selectivity | 488 |
| 2. Inhibition of Mast Cell Reactions Provoked by Stimuli Other Than Antigen-Antibody Interactions | 497 |
| 3. Time Course Studies | 500 |
| 4. Tachyphylaxis | 504 |
| IV. Studies of the Mechanism of Anti-Allergic Action | 506 |
| V. Other Pharmacological Effects | 511 |
| VI. Pharmacokinetics | 511 |
| C. Other Inhibitors of Mediator Release | 512 |
| I. Isosteres of Theophylline | 512 |
| 1. Structure-Activity Relationships | 512 |
| 2. Anti-Allergic Properties | 514 |
| II. Antihistamines and Histamine | 515 |
| III. Diethylcarbamazine | 517 |
| 1. Rat Peritoneal Cells in vivo | 517 |
| 2. Lung Tissue | 518 |
| 3. Human Leucocytes | 519 |
| 4. Passive Cutaneous Anaphylaxis Reactions | 519 |
| IV. Chlorphenesin | 519 |
| D. Prospects for New Drugs | 520 |
| References | 520 |

CHAPTER 35

Cytostats With Effects in Chronic Inflammation. K. BRUNE and M. W. WHITEHOUSE.
With 1 Figure

| | |
|--|-----|
| A. Introduction | 531 |
| B. General Pharmacology of Cytostats Effective in Chronic Inflammation | 534 |
| I. „Immunosuppressants“ | 537 |
| 1. Alkylating Agents | 540 |
| 2. Anti-Metabolites | 545 |
| II. Microtubular Inhibitors | 547 |
| 1. Colchicine | 548 |
| C. Some Properties of Selected Compounds | 552 |
| I. Microtubular Inhibitors | 552 |
| 1. Cytostatic Effects of Colchicine | 552 |
| II. Cyclophosphamide | 553 |
| 1. Metabolism | 553 |
| 2. Properties of Some Metabolites | 558 |
| 3. Site of Action | 559 |
| 4. Some Side-Effects | 560 |

| | |
|---|-----|
| III. Chlorambucil | 561 |
| 1. Metabolism | 561 |
| 2. Anti-Inflammatory Effects | 561 |
| 3. Mode of Action | 561 |
| IV. Methotrexate | 562 |
| V. Azathioprine | 563 |
| D. Current Problems | 564 |
| Appendix. Synovectomy and Destruction of Pannus | 565 |
| References | 566 |
| Addendum | 577 |

CHAPTER 36

Control of Hyperuricemia. J. KOVARSKY and E. W. HOLMES. With 2 Figures

| | |
|---|-----|
| A. Introduction | 579 |
| B. Uric Acid Metabolism | 579 |
| C. Biochemical Pharmacology of Hypouricemic Drugs | 581 |
| I. Drugs Reducing Uric Acid Synthesis | 581 |
| 1. Allopurinol and Oxipurinol | 581 |
| 2. Thiopurinol | 583 |
| 3. Other Inhibitors of Uric Acid Synthesis | 584 |
| II. Uricosuric Agents | 584 |
| III. Uricolytic Agents | 587 |
| D. Clinical Use of Hypouricemic Drugs | 587 |
| I. Criteria for Selecting a Hypouricemic Drug | 587 |
| II. Use of Individual Hypouricemic Drugs | 588 |
| III. Toxicity of Hypouricemic Agents | 589 |
| References | 590 |

CHAPTER 37

Anti-Inflammatory Steroids: Mode of Action in Rheumatoid Arthritis and Homograft Reaction. M. K. JASANI. With 19 Figures

| | |
|--|-----|
| A. General Considerations | 598 |
| B. Scope of the Review | 600 |
| C. Naturally Occurring Anti-Inflammatory Steroids | 602 |
| D. Synthetic Anti-Inflammatory Steroids | 604 |
| E. Biological Activities Observed With Physiological Amounts of Cortisol-Like Steroids | 604 |
| I. Metabolic Effects | 606 |
| 1. Gluconeogenesis | 606 |
| 2. Protein Metabolism | 606 |
| 3. DNA Synthesis | 607 |
| 4. Molecular Basis for Metabolic Effects | 608 |
| 5. Onset and Duration of Cortisol Action | 609 |

| | |
|--|-----|
| 6. Mechanism of Action of Cortisol | 609 |
| 7. Glycogenolysis | 610 |
| 8. Lipolysis | 610 |
| 9. Relationship to Anti-Inflammatory, Anti-Allergic and Anti-Rheumatic Action | 611 |
| 10. Relationship to Clinically Undesirable Effects | 613 |
| 11. Implications for the Future | 614 |
| II. Sodium Retaining Activity | 615 |
| III. Control of Adrenocorticotrophic Hormone (ACTH) Synthesis and Secretion | 617 |
| 1. Neuroendocrine Control | 618 |
| 2. Negative Feedback Control | 619 |
| 3. Basis for Negative Feedback Control | 620 |
| 4. Role of Cytoplasmic Steroid Receptors | 620 |
| 5. Relationship to Clinically Desirable Effects | 620 |
| 6. Relationship to Clinically Undesirable Effects | 621 |
| IV. Cardiovascular Effects | 622 |
| 1. Heart and Peripheral Blood Vessels in Adrenalectomised State | 622 |
| 2. Microcirculation | 622 |
| 3. Relationship to Anti-Inflammatory, Anti-Allergic, and Anti-Rheumatic Action | 626 |
| 4. Relationship to Clinically Undesirable Effects | 629 |
| 5. Pharmacological Implications | 633 |
| F. Mode of Action in Homograft Reaction | 634 |
| I. Interference With the Development of Circulating Sensitized Lymphocytes | 639 |
| II. Effectiveness Against Inflammation Due to Locally Sensitized Lymphocytes | 641 |
| III. Effectiveness Against Inflammation Due to Circulating Sensitized Lymphocytes | 642 |
| IV. Clinical Relevance of Experimental Observations | 645 |
| V. Relevance to Evaluation of More Effective Anti-Rejection and Anti-Rheumatic Drugs | 646 |
| G. Concluding Remarks | 647 |
| References | 648 |

CHAPTER 38

Anti-Inflammatory Agents of Animal Origin. M. J. H. SMITH and A. W. FORD-HUTCHINSON

| | |
|--|-----|
| A. Introduction | 661 |
| B. Definition and Evaluation of Anti-Inflammatory Activity | 661 |
| C. Mechanisms of Action | 663 |
| D. Individual Agents | 666 |
| I. Alkoxyglycerols | 666 |
| II. N(2-hydroxyethyl) Palmitamide | 667 |

| | |
|---|-----|
| III. Vitamins | 668 |
| IV. Amino Acids | 669 |
| V. Peptides | 669 |
| 1. Peptide 401 | 669 |
| 2. Rabbit Skin Protease Inhibitor | 671 |
| 3. Aprotinin (Trasylol) | 671 |
| VI. Proteins | 672 |
| 1. Exogenous Enzymes | 672 |
| 2. Orgotein | 673 |
| 3. Inflamed Tissue Factors | 675 |
| 4. Antileucotactic Agents | 677 |
| 5. Antiproliferative Agents | 680 |
| 6. Antilymphocytic Serum | 681 |
| VII. Tissue Hydrolysates | 682 |
| 1. Catrix | 682 |
| 2. Livingston Lysate | 683 |
| 3. Lysoartrosi | 683 |
| VIII. Human Plasma Factor | 684 |
| IX. Prostaglandins | 686 |
| E. Summary and Conclusions | 687 |
| References | 688 |

CHAPTER 39

Anti-Inflammatory Substances of Plant Origin. M. GÁBOR

| | |
|--|-----|
| A. Introduction | 698 |
| B. Anti-Inflammatory Action of Phenylbenzo- γ -Pyrone (Flavone) Derivatives | 698 |
| I. The Occurrence of Flavonoid Compounds in Nature | 698 |
| II. The Chemistry of Flavonoid Compounds | 698 |
| III. The Anti-Inflammatory Action of Flavonoids | 701 |
| 1. Influence on Mouse and Rat Paw Oedema | 701 |
| 2. Generalized Dextran Oedema in Rats | 705 |
| 3. Generalized Phospholipase Oedema in Rats | 705 |
| 4. Effect on the Development of the Granuloma Pouch | 706 |
| 5. Inflammation Caused by Cotton Pellet | 706 |
| 6. Erythema Produced by UV Radiation | 707 |
| 7. Inflammation Produced by Mustard Oil | 708 |
| 8. Influence on the Permeability-Increasing Action of Inflammatory Exudate | 708 |
| 9. Influence on the Inflammation Produced by Red Paprika (<i>Capsicum annuum</i> L. Solanaceae) | 709 |
| 10. Effect of Citrus Flavonoid Complex on Experimentally Induced Mucous Membrane Inflammation | 709 |
| 11. Influence on Experimentally Induced Thrombophlebitis | 710 |
| 12. Allergic and Hyperimmune Inflammation of the Skin and Joints . | 711 |

| | |
|---|-----|
| 13. Data on the Mechanism of the Anti-Inflammatory Effect of Flavonoids | 711 |
| 14. Discussion | 718 |
| C. Anti-Inflammatory Activity of Natural Plant Coumarins (Benzo- α -Pyrones) | 720 |
| D. Anti-Inflammatory Activity of Natural Plant Triterpenoids | 723 |
| I. Escin | 723 |
| II. Gcyrrhetic Acid | 724 |
| III. Other Triterpenoids | 725 |
| E. Colchicine | 725 |
| F. Essential Components of Camomile | 726 |
| I. The Azulenes | 726 |
| II. (–)- α -Bisabolol | 728 |
| III. EN—IN—Dicycloether | 729 |
| IV. Flavonoids | 729 |
| G. Miscellaneous | 729 |
| References | 730 |

CHAPTER 40

A Critical Comparison of the Evaluation of Anti-Inflammatory Therapy in Animal Models and Man. P. J. L. HOLT. With 1 Figure

| | |
|--|-----|
| A. Introduction | 740 |
| B. Comparison of Models of Inflammation With the Human Situation | 742 |
| C. Analysis of Parameters of Inflammation in Man | 744 |
| I. Stiffness | 746 |
| II. Pain | 746 |
| III. Joint Tenderness | 747 |
| IV. Grip Strength | 747 |
| V. Joint Size | 748 |
| VI. Blood Flow and Vascular Permeability | 748 |
| VII. Radiographic Changes | 749 |
| VIII. Tests of Functional Ability | 750 |
| IX. Laboratory Assessment of Disease Activity | 750 |
| D. Clinical Trials | 751 |
| I. Objectives | 752 |
| 1. Improvement of Therapeutic Methods at Present Available | 752 |
| 2. Optimum Benefit in a Patient | 752 |
| 3. Improvement of Methods of Monitoring Inflammation in Patients | 752 |
| 4. Development of New Human Models for the Evaluation of Drugs | 752 |
| 5. Discovery of New Therapeutic Agents | 753 |
| 6. Promotion of Scientific Management of Disease | 753 |
| II. Assessment | 754 |
| III. Patient Selection | 755 |
| IV. Placebo Response | 757 |
| V. Conclusions | 758 |

| | |
|--|-----|
| E. Treatment | 758 |
| I. Rest | 759 |
| II. Heat | 759 |
| III. Exercise | 759 |
| IV. Anti-Inflammatory Therapy | 760 |
| 1. Non-Steroid Anti-Inflammatory Drugs | 760 |
| 2. Gold, Penicillamine, and Chloroquine | 761 |
| 3. Corticosteroids | 763 |
| 4. Cytotoxic (Immunosuppressant) Therapy | 763 |
| 5. Local Anti-Inflammatory Therapy | 763 |
| 6. Lymphocyte Depletion | 764 |
| 7. Immune Potentiation | 764 |
| 8. Removal of Antibody | 764 |
| 9. X-Ray Irradiation | 764 |
| F. Summary | 764 |
| References | 765 |
| Author Index | 767 |
| Subject Index | 863 |